A detailed history of Raymond James & Associates transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 10,912 shares of LXRX stock, worth $8,293. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,912
Previous 10,912 -0.0%
Holding current value
$8,293
Previous $18,000 5.56%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$1.54 - $2.28 $109 - $161
71 Added 0.65%
10,912 $18,000
Q3 2023

Oct 24, 2023

SELL
$1.06 - $2.33 $245 - $540
-232 Reduced 2.1%
10,841 $11,000
Q2 2023

Jul 25, 2023

BUY
$2.15 - $3.49 $23,806 - $38,644
11,073 New
11,073 $25,000
Q4 2017

Feb 14, 2018

SELL
$8.77 - $12.28 $296,680 - $415,420
-33,829 Closed
0 $0
Q3 2017

Nov 13, 2017

SELL
$12.17 - $16.3 $12,474 - $16,707
-1,025 Reduced 2.94%
33,829 $416,000
Q2 2017

Aug 14, 2017

BUY
N/A
34,854
34,854 $573,000

Others Institutions Holding LXRX

About LEXICON PHARMACEUTICALS, INC.


  • Ticker LXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,726,000
  • Market Cap $143M
  • Description
  • Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...
More about LXRX
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.